Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Annayyaon Nov 06, 2020 10:35pm
139 Views
Post# 31856648

RE:RE:RE:RE:RE:RE:RE:Biogen's success has nothing to do with PMN

RE:RE:RE:RE:RE:RE:RE:Biogen's success has nothing to do with PMNI feel that this question is targeted towards my ask for why it's taking so long to complete the identification of neutralizing antibodies for COVID-19 test. There could be valid reasons, one of which is the cost involved perhaps in getting it done but thats why we have a very highly paid executive team, and it's their job to figure it out and get the funds needed to complete the job in a timely manner, before we lose the opportunity of monetizing the IP by generating revenue.
retiredcop wrote: This is a question for annaya... 

retiredcop wrote: With your expereince and connections to labs and daignsotics... any idea how much a Qaunterix Simoa HD- X Ananlyzer would cost and what would it take and how long to calibrate your own reagents .. known as "homebrew" , Also if you have 8 different reagents, can you use the same instrument for all variaitions or does each reagent need its own instrument.  Just something I cant seem to find out there. 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse